James Flanagan

Imperial College London

Dr James Flanagan, completed his PhD in 2002 at the Queensland Institute of Medical Research in Brisbane, Australia, and has pursued postdoctoral work in Cancer Genetics, Epigenetics and Cancer Epigenetics. He was awarded a Breast Cancer Campaign Scientific Fellowship (Imperial, 2009-2014) and is now a Senior Lecturer (2014-present) in the Division of Cancer, Dept. of Surgery and Cancer, Faculty of Medicine at Imperial College London. He was awarded the British Association of Cancer Research Translational Researcher Award in 2011 and is the principal investigator for the OCA funded programme "Risk and Prevention" based in the Ovarian Cancer Action Research Centre. Current research is aimed at investigating epigenetic alterations as a mechanism for carcinogenesis and investigating the hypothesis that epigenetic variation may be a driver of cancer risk whether by inherent constitutional variation or as a mediator of other cancer risk factors.

dont miss

Epigenetic biomarkers for platinum response in ovarian cancer

Platinum based chemotherapy is the standard of care for ovarian cancer patients at first line treatment and often at subsequent relapses. We have identified and validated an epigenetic biomarker detectable in blood DNA that predicts whether a patient should be treated with platinum after relapse. We propose a mechanism by which platinum-adduct DNA repair causes the epigenetic changes and that the genomic and epigenomic location of platinum adducts defines sensitivity.

James Flanagan will be speaking in the following theatre:

EVEN MORE SEMINARS

  • Ms Claire Barnard: Speaking at the Oncology Convention

    Ms Claire Barnard
    GenesisCare

    Surface-Guided Radiotherapy and Optimal Breast Cancer Treatment

  • Simon Walker-Samuel: Speaking at the Oncology Convention

    Simon Walker-Samuel
    University College London

    Using medical imaging with machine learning to develop efficient tools for diagnosing cancer

  • Dr Bernadette A Lavery: Speaking at the Oncology Convention

    Dr Bernadette A Lavery
    GenesisCare

    Surface-Guided Radiotherapy and Optimal Breast Cancer Treatment

  • Joanne Edwards: Speaking at the Oncology Convention

    Joanne Edwards
    University of Glasgow

    Role of IKK alpha in Breast Cancer

  • Sally Hayes: Speaking at the Oncology Convention

    Sally Hayes
    Maggie’s

    Maggie’s programme of emotional support